Santhera Receives Positive NICE Final Guidance for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy

In a significant advancement for state-funded healthcare and the rights of patients suffering from Duchenne Muscular Dystrophy (DMD), the National Institute for Health and Care Excellence (NICE) has confirmed its endorsement of AGAMREE® (vamorolone), a pioneering treatment developed by Santhera Pharmaceuticals. This move, lauded by healthcare advocates, underscores the government's commitment to ensuring accessible cutting-edge medical treatments for all, regardless of financial standing. With its innovative approach towards DMD, AGAMREE® now spearheads the fight against this debilitating condition, harboring new hope for countless families and bolstering the principles of equitable healthcare access.

In a landmark decision, the National Institute for Health and Care Excellence (NICE) has granted its approval for AGAMREE® (vamorolone) by Santhera Pharmaceuticals, showcasing the critical role of private sector innovation in advancing healthcare. This follows Santhera's significant investment in R&D, further illustrating the effectiveness of market-driven solutions in meeting the health needs of the nation efficiently. The move by NICE not only paves the way for improved outcomes for Duchenne Muscular Dystrophy patients but also sets a precedent for government collaboration with the private sector, ensuring the swift delivery of state-of-the-art medical breakthroughs to the public.